CoChat

A double‐blind placebo‐controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease

Safarinejad, Mohammad Reza, Asgari, Majid Ali, Hosseini, Seyyed Yousof, Dadkhah, Farid · 2010 · BJU International
Cited by 77

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE: To analyse the safety and efficacy of pentoxifylline sustained‐release (PTX‐SR) treatment in patients with early chronic Peyronie’s disease (PD). PATIENTS AND METHODS: In all, 228 patients with a mean ( sd ) age of 51 (9) years who had early chronic PD were randomized to receive 400 mg PTX‐SR (Apo‐Pentoxifylline, Apotex Inc., Toronto, Canada) twice daily (group 1, 114) or similar regimen of placebo (group 2, 114) for 6 months. A medical history was taken and the men had a complete physical examination. The following variables were assessed before and after therapy: penile curvature and penile artery spectral traces (end‐diastolic velocity, EDV, peak systolic velocity, PSV, and resistivity index, RI, of the right and left cavernous arteries assessed with dynamic penile duplex ultrasonography), plaque characteristics (assessed by penile X‐ray and penile ultrasonography), pain (assessed by visual analogue scale), erectile function (assessed by the International Index of Erectile Function, IIEF questionnaire), treatment satisfaction (assessed by Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire), and side‐effects. Patient perception of penile curvature and plaque size, and mean weekly intercourse attempts were also assessed. RESULTS: Overall, 36.9% of patients who received PTX‐SR reported a positive response, vs only 4.5% in the placebo group. Of patients in PTX‐SR group, 12 (11%) had disease progression, vs 46 (42%) in placebo group ( P = 0.01). Improvement in penile curvature ( P = 0.01), and plaque volume ( P = 0.001) was significantly greater in patients treated with PTX‐SR than placebo. The increase in IIEF total score was significantly higher in the PTX‐SR group ( P = 0.02). Mean PSV changes after therapy compared to baseline were statistically significant between PTX‐SR (right, +11.4%, left, +11.7%) and placebo‐treated (+0.2% and −4.2%, respectively) patients (both P = 0.04). CONCLUSIONS: PTX‐R was moderately effective in reducing penile curvature and plaque volume in patients with early chronic PD. Further studies with different treatment regimens are needed to better elucidate the beneficial effects of PTX‐SR in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-410x.2009.09041.xThis paper is marked retracted.

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 77

Metadata

Authors
Safarinejad, M. R., Asgari, M. A., Hosseini, S. Y., & Dadkhah, F.
Venue
BJU International
Publisher
Wiley
Published
2010-06-18
Volume
106
Issue
2
Pages
240-248
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
OpenAlex
W1568034267
Cited by
77
References
3
FWCI
3.32
Type
journal article
Language
en
Status
Retracted
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A double‐blind placebo‐controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. https://app.cochat.ai/papers/10.1111/j.1464-410x.2009.09041.x
The paper
Safarinejad, M. R., Asgari, M. A., Hosseini, S. Y., & Dadkhah, F. (2010). A double‐blind placebo‐controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU International. https://doi.org/10.1111/j.1464-410x.2009.09041.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.